Zobrazeno 1 - 10
of 29
pro vyhledávání: '"M.C.H. Ng"'
Autor:
L.A.L. Lee, C.H. Lim, W.H. Chan, M.L.K. Chua, W.Q. Leow, J.P.S. Yeong, S.J. Ong, C. Yip, J. Lin, T.R. Siow, E. Lim, J. Lee, J.Y.C. Lam, H.S. Ong, M.C.H. Ng, W.K. Wong, F. Wang, A.S.Y. Wong, T.K.H. Lim, L.M. Wang, A.K.H. Eng, E. Ong, S.Z. Ho, F.W.T. Lim, M.L.C. Wang
Publikováno v:
Radiotherapy and Oncology. 152:S550-S551
Autor:
M. Rosales, Kian-Huat Lim, A. Wynter-Horton, K.-W. Lee, Y.-J. Bang, T. Wu, Jan Baughman, K. Huber, Haeseong Park, Philip J. Gold, Hope E. Uronis, Jan K Davidson-Moncada, Jill Lacy, Y-K. Kang, S.H. Park, Daniel Virgil Thomas Catenacci, M.C.H. Ng, Peter C. Enzinger, Jon M. Wigginton, J. Nordstrom
Publikováno v:
Annals of Oncology. 30:v484-v485
Autor:
Haeseong Park, John Muth, Jan K Davidson-Moncada, Keun Wook Lee, Amy Sullivan, Stephen Reeder, Sarah Warren, Sarah E. Church, A. Wynter-Horton, Hope E. Uronis, Jayakumar Vadakekolathu, K. Huber, Y.-J. Bang, D. Li, Y-K Kang, Daniel V.T. Catenacci, Sergio Rutella, M.C.H. Ng, Peter C. Enzinger, Jan Baughman
Publikováno v:
Annals of Oncology. 30:v38-v39
Background Despite improvements in treatments, the 5-year survival of GEA patients (pts) is disappointing. Individual molecular subtypes display preferential responses to PD-1 blockade. M, an investigational Fc-optimized anti-HER2 monoclonal antibody
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
W.K. Wong, W.H. Chan, L.M. Wang, J.P.S. Yeong, C.H. Lim, M.L.K. Chua, F. Wang, Molin Wang, J. Lin, A. Eng, S. Ho, J. Lam, T.K.H. Lim, J. Lee, F. Lim, E.K.W. Lim, H.S. Ong, T.R. Siow, A. Wong, M.C.H. Ng, C.S.P. Yip, L.A.L. Lee, E.H.W. Ong, W.Q. Leow
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:e604
Autor:
J. Nordstrom, Jayakumar Vadakekolathu, Courtney L. Erskine, John Muth, Hope E. Uronis, Sergio Rutella, Keun Wook Lee, Y-K. Kang, M.C.H. Ng, Daniel V.T. Catenacci, Sarah E. Church, J. Yen, Y.-J. Bang, M. Rosales, Jan K Davidson-Moncada, Peter C. Enzinger, Aleksandra Franovic, Haeseong Park, Keith L. Knutson, T. Wu
Publikováno v:
Annals of Oncology. 30:v485
Background T + chemo is standard 1st line therapy for HER2+ gastroesophageal adenocarcinoma; however, patients (pts) tend to progress in 6-8 months. Up to 40% show loss of HER2 expression post T, likely underlying the lack of efficacy of anti-HER2 ag
Autor:
S.P. Choo, Aaron Tan, C. Lim, M.C.H. Ng, D.W.M. Tai, W.T. Teng, Y.C.J. Lam, K.H. Lim, A.O.L. Seet
Publikováno v:
Annals of Oncology. 30:v178
Background VAR is a potent TKI against EGFR, HER2 and HER4. Efficacy of VAR combined with fluoropyrimidine and platinum chemo in colorectal cancer (CRC) and biliary tract cancer (BTC) has been reported (ESMO 2018 430P, GI ASCO 2019 #319). Methods Pat
Autor:
G. Li, David Wai-Meng Tai, M.C.F. Macapagal, D.S.W. Tan, T.W.K. Tan, S.P. Choo, Wan-Teck Lim, M.L. Goh, A. Ahmad, M.C.H. Ng, A. Seet
Publikováno v:
Annals of Oncology. 30:v173
Background Recombinant super-compound interferon (rSIFN-co) is a new class of interferon derived from altering the spatial structure and configuration of the basic interferon protein. rSIFN-co displayed greater anti-tumor activity in solid tumors com
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Daniel V.T. Catenacci, Jon M. Wigginton, Philip J. Gold, T. Wu, Hope E. Uronis, Keun Wook Lee, Haeseong Park, J. Yen, A. Wynter-Horton, Y.-J. Bang, Aleksandra Franovic, John Muth, Peter C. Enzinger, Jill Lacy, Justin I. Odegaard, Y-K. Kang, M.C.H. Ng, Sung-Ji Park, Jan Baughman, Jan K Davidson-Moncada
Publikováno v:
Annals of Oncology. 29:viii223